272 related articles for article (PubMed ID: 22924434)
1. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
[TBL] [Abstract][Full Text] [Related]
3. Bromodomains as therapeutic targets.
Muller S; Filippakopoulos P; Knapp S
Expert Rev Mol Med; 2011 Sep; 13():e29. PubMed ID: 21933453
[TBL] [Abstract][Full Text] [Related]
4. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
5. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
6. The bromodomain: from epigenome reader to druggable target.
Sanchez R; Meslamani J; Zhou MM
Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
[TBL] [Abstract][Full Text] [Related]
7. Bromodomains and their pharmacological inhibitors.
Gallenkamp D; Gelato KA; Haendler B; Weinmann H
ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
[TBL] [Abstract][Full Text] [Related]
8. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
9. Biochemical profiling of histone binding selectivity of the yeast bromodomain family.
Zhang Q; Chakravarty S; Ghersi D; Zeng L; Plotnikov AN; Sanchez R; Zhou MM
PLoS One; 2010 Jan; 5(1):e8903. PubMed ID: 20126658
[TBL] [Abstract][Full Text] [Related]
10. Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target Validation.
Schiedel M; Moroglu M; Ascough DMH; Chamberlain AER; Kamps JJAG; Sekirnik AR; Conway SJ
Angew Chem Int Ed Engl; 2019 Dec; 58(50):17930-17952. PubMed ID: 30633431
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
12. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain.
Morinière J; Rousseaux S; Steuerwald U; Soler-López M; Curtet S; Vitte AL; Govin J; Gaucher J; Sadoul K; Hart DJ; Krijgsveld J; Khochbin S; Müller CW; Petosa C
Nature; 2009 Oct; 461(7264):664-8. PubMed ID: 19794495
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
[TBL] [Abstract][Full Text] [Related]
14. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.
Chandrasekaran R; Thompson M
Biochem Biophys Res Commun; 2007 Apr; 355(3):661-6. PubMed ID: 17320048
[TBL] [Abstract][Full Text] [Related]
15. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex.
Singh M; Popowicz GM; Krajewski M; Holak TA
Chembiochem; 2007 Jul; 8(11):1308-16. PubMed ID: 17582821
[TBL] [Abstract][Full Text] [Related]
16. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
Sasaki K; Yoshida M
Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
[TBL] [Abstract][Full Text] [Related]
17. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain Histone Readers and Cancer.
Jain AK; Barton MC
J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
[TBL] [Abstract][Full Text] [Related]
19. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
20. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
